hrp0086p1-p214 | Diabetes P1 | ESPE2016

Analysis of Short-Term Efficacy of MiniMed 640G with SmartGuard in Pediatric Patients with Type 1 Diabetes

Villafuerte Beatriz , Martin-Frias Maria , Yelmo Rosa , Roldan Belen , Angeles Alvarez M. , Barrio Raquel

Background: Fear of hypoglycemia is a major constraint on achieving a good metabolic control in T1D. Sensor augmented insulin pump therapy with threshold-suspended features (MiniMed 640G-SG) might alleviate burden of hypoglucemia and improve outcomes.Objective and hypotheses: Evaluate the effectiveness of this system to prevent day and night hypoglycemia and its impact on HbA1c in a pediatric population with T1D.Method: Descriptive...

hrp0086p2-p265 | Diabetes P2 | ESPE2016

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion Treatment in Pre-schoolers. Long Term Experience of a Tertiary Care Centre in Spain

Colino Esmeralda , Villafuerte Beatriz , Martin Maria , Roldan Belen , Alvarez Angeles , Yelmo Rosa , Barrio Raquel

Background: There is limited knowledge in children younger than 6 years of age about the safety and efficacy of CSII treatment during long periods of time.Objective and hypotheses: Evaluate the efficacy and safety of CSII treatment in pre-schoolers with T1D, assess if ISPAD/ADA criteria for good metabolic control are achieved and define general and specific characteristics of the treatment in this range of age.Method: Charts of pat...

hrp0084p3-1021 | Growth | ESPE2015

Response to rhGH Treatment in Patients with Transient or Permanent GH Deficiency

Villafuerte Beatriz , Barrio Raquel , Martin-Frias Maria , Alonso Milagros , Oyakawa Yoko , Roldan Belen

Background: GH (rhGH) treatment improves adult height in GH deficient (GHD) patients. However, there are differences in short and long term responses to treatment between children with permanent deficit (PDGH) and those who present a transient deficit (TDGH) when reassessed at final height (FH).Objective and hypotheses: To evaluate the response to rhGH treatment in patients with PDGH or TDGH one year after initiating treatment and at FH when treatment wa...

hrp0086p1-p909 | Thyroid P1 | ESPE2016

Identification of a “Cryptic” De Novo Deletion in NKX2.1 in the Brain-Lung-Thyroid Syndrome using Genomic SNP Arrays

Villafuerte Beatriz , de Benito Daniel Natera , Lacamara Nerea , Garcia Marta , Lumbreras Cesar , de Randamie Rajdee , Nevado Julian , Moreno Jose Carlos

Background: Genetic defects in NKX2.1 (chromosome 14q13) are associated with hypothyroidism, choreo-athetotic movements and respiratory distress, known as the “Brain-Lung-Thyroid syndrome”.Objective and hypotheses: To identify the genetic basis of a disorder compatible with the “NKX2.1 syndrome” and extra features outside the typical triad.Patients and methods: 10-year old girl with congenital ...